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Approaches for classifying the indications for
colonoscopy using detailed clinical data
Hirut Fassil1, Kenneth F Adams2, Sheila Weinmann3, V Paul Doria-Rose4, Eric Johnson5, Andrew E Williams6,
Douglas A Corley7 and Chyke A Doubeni8,9,10*
Abstract
Background: Accurate indication classification is critical for obtaining unbiased estimates of colonoscopy effectiveness
and quality improvement efforts, but there is a dearth of published systematic classification approaches. The objective of
this study was to evaluate the effects of data-source and adjudication on indication classification and on estimates of the
effectiveness of screening colonoscopy on late-stage colorectal cancer diagnosis risk.
Methods: This was an observational study in members of four U.S. health plans. Eligible persons (n = 1039) were age
55–85 and had been enrolled for 5 years or longer in their health plans during 2006–2008. Patients were selected based
on late-stage colorectal cancer diagnosis in a case–control design; each case patient was matched to 1–2 controls by
study site, age, sex, and health plan enrollment duration. Reasons for colonoscopies received in the 10-year period before
the reference date were collected from three medical records sources (progress notes; referral notes; procedure reports)
and categorized using an algorithm, with committee adjudication of some tests. We evaluated indication classification
concordance before and after adjudication and used logistic regressions with the Wald Chi-square test to compare
estimates of the effects of screening colonoscopy on late-stage colorectal cancer diagnosis risk for each of our data
sources to the adjudicated indication.
Results: Classification agreement between each data-source and adjudication was 78.8-94.0% (weighted kappa
= 0.53-0.72); the highest agreement (weighted kappa = 0.86-0.88) was when information from all data sources was
considered together. The choice of data-source influenced the association between screening colonoscopy and
late-stage colorectal cancer diagnosis; estimates based on progress notes were closest to those based on the
adjudicated indication (% difference in regression coefficients = 2.4%, p-value = 0.98), as compared to estimates from
only referral notes (% difference in coefficients = 34.9%, p-value = 0.12) or procedure reports (% difference in coefficients
= 27.4%, p-value = 0.23).
Conclusion: There was no single gold-standard source of information in medical records. The estimates of colonoscopy
effectiveness from progress notes alone were the closest to estimates using adjudicated indications. Thus, the details in
the medical records are necessary for accurate indication classification.
Background
There is a critical need for valid comparative effective-
ness studies of cancer screening tests, but this is often
hampered by uncertainties about the exact reason for
testing. This is particularly important for observational
studies that seek to determine the effectiveness of colo-
rectal cancer (CRC) screening. There are multiple testing
options available for CRC, [1,2] which differ in the
strength of the evidence supporting their use, [3-11] and
in their benefits, harms, costs, and complexity [3,12].
In the United States, colonoscopy is the most com-
monly used CRC screening test, [13] but it is also used
in the diagnosis and surveillance of colorectal neoplasia
[14]. Thus, the accurate determination and classification
of the reasons for testing is crucial to the validity of
observational studies of colonoscopy’s effectiveness and
for guiding quality improvement efforts [15]. Further,
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the documented test indication, such as a prior diagnosis
of adenoma or family history of CRC, guides clinicians
in making follow-up recommendations [1,16,17]. How-
ever, there is currently a paucity of published studies on
the process of using clinical data to assign indication.
The true indication for colonoscopy is the clinical ra-
tionale for the referral for testing, but this is difficult to
measure from medical records or administrative data
because the reasons for testing are not consistently doc-
umented [18]. Assigning an indication may also be diffi-
cult due to the multiplicity of reasons often recorded for
a particular test or when common gastrointestinal symp-
toms, which have a low predictive value for CRC diagno-
sis, [19-21] are recorded at the time a colonoscopy is
recommended or performed [15]. Therefore, colonoscopy
indication derived from clinical or administrative data may
be misclassified, leading to biased results in observational
studies of screening colonoscopy effectiveness.
This study describes an algorithm and an adjudication
approach for classifying colonoscopy indications using
clinical data. We also determined the extent to which
estimates of colonoscopy effectiveness based on pre-
adjudication indication classification differed from an ad-
judicated reference standard by estimating the effect of
screening colonoscopy on the risk of diagnosis with inci-
dent late-stage CRC.
The currently used approaches and published algo-
rithms for assigning indication have not been validated
against a standardized classification approach. Previous
studies on classifying colonoscopy indication have sim-
ply been based on diagnosis and procedure codes in
administrative or claims data that indicate the presence
or absence of gastrointestinal-related procedures, signs,
symptoms or conditions [22-25]. These algorithms can
produce different classification results, depending on the
codes used or the length of time prior to the test that
was evaluated for ascertaining the presence or absence
of gastrointestinal conditions. This can lead to unex-
pected results when evaluating the effectiveness of
colonoscopy in observational data, [15,26] underscoring
the need for a standardized approach for indication
classification.
Methods
The data were obtained from a case–control study of
the comparative effectiveness of CRC screening tests [4].
Study patients were 55–85 years old between January 1,
2006 and December 31, 2008 and had been enrolled for
≥5 years in one of the following managed care plans:
Group Health Cooperative, Washington State; Kaiser
Permanente Hawaii; Kaiser Permanente Northwest; and
Reliant Medical Group/Fallon Community Health Plan,
Massachusetts. These health plans have used electronic
medical records systems since at least 2005 and have
electronic healthcare utilization data dating back to 1995
or earlier. This study was approved by the Institutional
Review Boards at the University of Pennsylvania, the
University of Massachusetts Medical School (UMMS),
Group Health Research Institute (GHRI), and through
ceded human subjects oversight authority from Reliant
Medical Group to UMMS, and from Kaiser Permanente
Hawaii and Kaiser Permanente Northwest to GHRI.
The outcome of the study was a diagnosis of incident
late-stage CRC, defined as American Joint Commission
on Cancer (Sixth Edition) stage IIB or higher based on
tumor registry data [4,27]. Each patient with late-stage
CRC (n = 498) was matched on the diagnosis (reference)
date to 1–2 CRC-free controls (n = 541) by study site,
birth year, sex, and health plan enrollment duration, as
described elsewhere [4]. Data on the matching variables,
socioeconomic factors, and patients’ clinical history were
collected from electronic databases, tumor registry, and
census data. Information on family history of CRC was
obtained from electronic or paper medical records.
Data collection on colonoscopy and other CRC tests
The primary interest in this report was the concordance
of indication across multiple data sources for colonos-
copies received during the 10-year period before the ref-
erence date (observation period), which was determined
from data collected from each patient’s medical records
(see Additional file 1: Appendix A). Trained abstractors,
one each at three study sites and two at one site, per-
formed the medical record audits. Audits were standard-
ized through training and retraining and through the use
of a common, structured electronic data collection instru-
ment that was developed in Microsoft Access. The data
collection tool was pre-populated with patient demo-
graphics, health care utilization history and the dates of
CRC tests that were extracted from electronic databases
using, in part, codes from the International Classification
of Diseases, 9th Edition, Clinical Modification, Current
Procedural Terminology and Healthcare Common Pro-
cedure Coding System [28]. For each test found in the
medical records, the auditors collected up to three docu-
mented reasons, separately, from each of three data
sources (progress notes, referral note, and procedure re-
port) according to 28 pre-coded categories (see Additional
file 1: Appendix B). Auditors also collected reason-related
information in free-text format. We defined the progress
notes as all parts of the medical records other than the re-
ferral note and procedure-related documentation.
Similar data were collected on sigmoidoscopy, double
contrast barium enema (BE), and CT colonography (CTC),
which aided in indication classifications. Detailed data on
fecal occult blood test (FOBT) restricted to the 5-year
period before the reference date were also collected, includ-
ing whether a test was positive or negative and the type of
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diagnostic test received following positive results. Auditors
coded FOBT reasons as screening, diagnostic, surveillance,
other, or unknown.
Indication classification using a decision algorithm
We first used a computer-based decision algorithm to clas-
sify the indication for each colonoscopy test (test-level clas-
sification) into one of eight mutually exclusive categories: 1)
surveillance, 2) ‘definite’ diagnostic, 3) ‘probable’ diagnostic,
4) ‘possible’ diagnostic, 5) ‘probable’ screening, 6) ‘definite’
average-risk screening, 7) ‘high-risk’ screening, or 8) un-
known (Figure 1), followed by review of the classifications
on selected tests (Figure 2). If a patient had multiple colon-
oscopies during the observation period, we derived a single
overall indication variable to characterize his/her colonos-
copy use (patient-level classification, described later).
A colonoscopy was classified as surveillance if per-
formed for follow-up of previously detected polyps; ‘def-
inite’ diagnostic if used to work-up a positive FOBT, a
mass or other abnormal finding; ‘probable’ diagnostic if
the medical records noted clinical conditions that were
deemed to represent a high pretest probability for CRC,
such as rectal bleeding; ‘possible’ diagnostic if the only
documented reasons were non-specific medical condi-
tions such as diarrhea or abdominal pain; or ‘probable’
screening if both non-specific symptoms and screening
were recorded. The indication was considered ‘high-risk’
screening if the test was performed for screening and
the patient had a first-degree relative diagnosed with
CRC before age 50, two or more second-degree relatives
diagnosed at any age, or other familial syndromes. The
indication was considered ‘definite’ average-risk screen-
ing if screening was recorded and none of the CRC
conditions or risk factors noted above were recorded.
The indication was considered unknown if the reason
was not specifically documented.
Review of test indication
The algorithm assigned each test a single indication
irrespective of the number of reasons (or missing data)
Figure 1 Decision algorithm for colonoscopy indication classification.
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recorded by chart auditors (see Figure 2). We therefore
identified tests that could have been misclassified in
order to review all available indication-related data. This
review was conducted in two steps. The first step deter-
mined whether or not a particular test required a formal
review by an adjudication panel of experts. Tests were
selected for the first-tier review if more than one indica-
tion could be assigned, or indication was unknown in all
data sources (Figure 2). For instance, a test was selected
for review if the referral note recorded both constipation
and average-risk screening or the indication differed (in-
cluding unknown) across data sources (i.e., classified as
‘probable’ diagnostic based on referral note but ‘prob-
able’ screening from progress notes). Because non-coded
information was not included in the algorithm, we also
reviewed all tests that had data in relevant free-text
variables.
Three investigators and a research assistant (KA and
see acknowledgement) performed the first-tier reviews
of indication data (in pairs). At this review, tests that
had additional pertinent indication-related information
in free-text data or had substantive discordance across
data sources were submitted for adjudication. Discordance
due to classification as ‘definite’ diagnostic versus ‘probable’
diagnostic was considered non-substantive. We required
consensus by both reviewers for a test to bypass adjudica-
tion. All tests classified as ‘high-risk’ screening were adjudi-
cated to evaluate the details of the CRC risk. Once a test
was selected for the first-tier review or adjudication, all the
CRC tests of the particular patient (except FOBTs) were
evaluated at the first-tier review, and/or adjudication, as ap-
propriate. Of the 647 colonoscopies observed in the sample,
454 underwent the first-tier review of which 304 were
reviewed by the adjudication panel (Figure 2).
Adjudication of test indication
We formed a 5-member panel of experts comprised of
epidemiologists, internists and gastroenterologists (DAC,
VPDR and see acknowledgement), and a non-voting chair
(CAD) to evaluate indication for the selected tests. The goal
of adjudication was to classify each test according to the
predetermined categories in Figure 1, after careful review of
all available data. The adjudication committee reviewed
tests blinded to the case–control status; study site; test type
and exact dates; and, in the case of patient with multiple
tests, whether a particular test was the trigger for adjudica-
tion. However, they were given the sequence and results of
FOBTs and the sequence and type of health care visits.
In assigning indication, the committee considered clin-
ical conditions that were documented as reasons for
CRC testing, in part, by grouping them as strong versus
non-specific based on the pretest probability of CRC
associated with each condition (Additional file 1: Appendix
C) [29,30]. Because gastrointestinal conditions are highly
prevalent but are individually not highly predictive for
CRC diagnosis [19,20,31], the grouping of clinical
conditions was largely based on panel consensus. Dis-
agreements among committee members on indication
assignment were resolved using a majority rule. How-
ever, tests classified by different committee members
as both screening and diagnostic were discussed until a
consensus was reached.
Assigning a single exposure variable per patient
Patients with multiple colonoscopies (n = 88) during the
observation period were assigned a single patient-level
indication in a temporally hierarchical manner by con-
sidering both the indication and the sequence of colon-
oscopies in relation to the reference date. We selected
Figure 2 Flow diagram of the derivation of indication variables for colonoscopy. *Up to three coded reasons were recorded from each
data source during the chart audit. †One indication variable was derived for each data source. ‡This is a single indication assigned to each test
combining all coded data collected on each test during chart audit using the computer algorithm shown in Figure 1. It combined data from
referral note, progress note and procedure report. §‘N’ is the number of patients. The numbers in parentheses are the tests received by the N
patients. ¶A test was selected for review if more than one indication could be assigned or was unknown in all data sources, or relevant free-text
data. #Tests on these patients were not selected for review and/or adjudication (see text).
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the ‘definite’ screening test with a test date that was far-
thest from the reference date; if none, then we used the
earliest ‘probable’ screening colonoscopy; and if none,
then ‘possible’ diagnostic, ‘probable’ diagnostic and fi-
nally ‘definite’ diagnostic colonoscopy, in that order. The
indication was classified as surveillance if the first colon-
oscopy was for surveillance and there was no subsequent
screening test.
Statistical analyses
For this report, we categorized the indication as routine
screening (‘probable’ or ‘definite’ average-risk screening),
‘high-risk’ screening, surveillance, ‘possible’ diagnostic,
diagnostic (‘definite’ or ‘probable’ diagnostic), or unknown.
Analyses were performed on both test-level (each colonos-
copy, n = 647) and patient-level (n = 524) classifications.
Pair-wise analyses compared the proportion classified in
each of the six indication categories among data sources
and with adjudication.
We calculated the percent concordance with adjudi-
cated indication, for each data source individually and
for all sources combined, in both test- and patient-level
analyses. In these analyses, we considered all indication
categories at the same time using a categorical variable,
and combined routine and ‘high-risk’ screening into a
single ‘screening’ category for ease of interpretation.
We also computed kappa (ĸ) coefficient of agreement
using quadratic weights that considered the most important
distinction as that between screening and diagnostic. The
kappa statistic was interpreted according to Byrt’s recom-
mendation (≤0.00 = no agreement; 0.01-0.20 = poor; 0.21-
0.40 = slight; 0.41-0.60 = fair; 0.61-0.80 = good; 0.81-0.92 =
very good; and >0.92 = excellent agreement) [32]. Kappa ac-
counts for the probability of chance by considering both
the observed and expected agreements. Thus, it can be
spuriously low when expected agreement is high, as
could occur in the case of indication classification due
to high correlation among data sources. Therefore, we
based our interpretation primarily on unweighted per-
centage concordance.
Next, we evaluated whether differences in the data
sources and classification approach for indication influ-
enced estimates of the association between exposure to
routine screening colonoscopy and diagnosis with late-
stage CRC. In secondary analyses, we used the expanded
screening definition that included ‘high risk’ screening.
Analyses were performed with conditional logistic re-
gression models, adjusting for census block-group pov-
erty levels (in quartiles), number of preventive health
care visits, family history of CRC, modified Charlson
comorbidity index at baseline, and receipt of other screen-
ing tests. We then computed the percentage difference in
beta coefficients between the algorithm-derived screening
indications and the adjudicated standard, and used two-
sided Wald χ2 P-values to evaluate the statistical signifi-
cance of the differences. In our regression analyses, we
accounted for the period of preclinical late-stage CRC by
excluding tests performed within one month of the
reference date, as described in a previous report [4].
The analyses were performed using STATA version
12.1 (StataCorp, College Station, TX, USA).
Results
The patients (n = 1,039) included in this report were
72 years old on average, with an equal percentage of
men and women (Table 1). Most had been members of
their health plan for 10 years or longer. The majority of
the colonoscopies received were for a diagnostic indication
(59.4-69.7%), irrespective of the classification scheme or
data source.
The algorithm-based colonoscopy indication was cate-
gorized as ‘unknown’ for 2.8% of tests when based on
the procedure report, 10.7% when based on the progress
notes, and 11.4% when based on the referral note
(Figure 3A). Compared to the procedure report, the pro-
gress note classified fewer tests as surveillance (13.9%
versus 10.0%, P-value = 0.03). In patient-level analyses
based on the algorithm-derived indications, a similar
percentage of patients were classified as screening across
the three data sources (progress note 9.4%, referral 9.7%
and procedure report 10.7%) or ‘high-risk’ (Figure 3B).
Indication classification after adjudication
The algorithm-based indications of the colonoscopies
reviewed by the committee were: screening = 21, ‘high-
risk’ = 21, surveillance = 80, ‘possible’ diagnostic = 8,
diagnostic = 170, and unknown = 4 (Additional file 1:
Appendix D). After the review, 16 (76.2%) indications
previously classified as screening remained unchanged,
but the remaining five were reclassified as ‘possible’
diagnostic (n = 2), diagnostic (n = 2) and surveillance
(n = 1). Nineteen of the 21 ‘high-risk’ tests (90.5%), six of
the 170 diagnostic (3.5%), one of the eight ‘possible’
diagnostic (12.5%) and two of the 80 surveillance tests
(2.5%) were reclassified as screening. The majority of
diagnostic tests (n = 155, 91.2%) remained unchanged;
five were reclassified as ‘possible’ diagnostic, three as
surveillance, and one as ‘high-risk’ screening. Only one
of the four ‘unknowns’ remained unchanged, with one
each of the remaining three reclassified as surveillance,
‘possible’ diagnostic and diagnostic.
Indication classification agreement
Next, we analyzed agreement on classification across the
indication categories. On individual colonoscopies (n =
647), the concordance on algorithm-based indication
among the three data sources ranged from 75.6% (pro-
gress note versus referral) to 81.5% (procedure report
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versus referral), which corresponded to fair-good agree-
ment on the kappa scale (ĸ = 0.53-0.66) (Figure 4). We
also found fair-to-good agreement between adjudication
and algorithm-based indication classification for each data
source alone (78.8-87.6%, ĸ = 0.56-0.72), but very good
agreement for all sources combined (93.0%, ĸ = 0.86).
In the patient-level analyses (n = 524), there was fair-
to-good agreement in exposure classification among the
three sources (76.9% to 82.3%, ĸ = 0.56-0.65) (Figure 4).
Compared to adjudication, there was fair-to-good agree-
ment with each of the data sources (progress note
80.2%, ĸ = 0.58; referral 84.0%, ĸ = 0.66; procedure re-
port 88.0%, ĸ = 0.71); the highest level of agreement was
with all sources combined (93.9%, ĸ = 0.88).
Effect on relationship between screening colonoscopy
and late-stage CRC
We then examined whether the differences in indication
classification across data sources affected estimates of
the effect of screening. We estimated effects of screening
colonoscopy on incident late-stage CRC diagnosis risk,
comparing algorithm-derived screening indications to
adjudication, according to the source of indication data.
We found that the associations of screening colonoscopy
with late-stage CRC diagnosis risk differed from the ad-
judicated standard by 2.4-34.9% (Table 2). The estimates
based on progress note information alone (P-values =
0.64-0.98) or in combination with the other two sources
(P-values = 0.52-0.69) showed relatively little difference
from adjudication. The estimates for the effects of screen-
ing colonoscopy on late-stage CRC based on analyses with
information from the referral (P-values = 0.12-0.41) or pro-
cedure report (P-values = 0.23-0.26) showed slightly more
deviation from the adjudicated standard than progress
notes (see Table 2).
Discussion
This study compared the information from different
clinical data sources for colonoscopy indication classifi-
cation and found generally good agreement among the
progress notes, referral note, and procedure report.
However, there were differences between sources in the
classification of tests as screening and the extent of
missing information. After adjudication, most patients
classified as ‘high-risk’ were determined to be average-
risk screening. Indication classification without expert
review resulted in a 2.4-34.9% deviation from the adjudi-
cated standard in the estimated effects of screening
colonoscopy. We found that, although the direction of
the association between screening colonoscopy and late-
stage CRC diagnosis risk was not changed by the indica-
tion data source, analyses with information from the
progress notes alone or in combination with referral and
procedure reports produced results that were closest to
those from the indication derived through adjudication.
The literature provides no consistent method for deter-
mining CRC test indication and no previously published
Table 1 Demographic and clinical characteristics of cases
and controls, SEARCH Study 2006–2008, n = 1,039
Characteristics Sample,
n = 1,039
Age, year
55-64 252 (24.3)
65-74 346 (33.3)
75-85 441 (42.4)
Female 515 (49.5)
Study site
A 206 (19.8)
B 386 (37.2)
C 129 (12.4)
D 318 (30.6)
Poverty levels, quartiles*
1 253 (24.4)
2 251 (24.2)
3 253 (24.4)
4 248 (23.9)
Missing 34 (3.3)
Length of enrollment with health plan before reference date, yr
5.0-7.4 172 (16.6)
7.5-9.9 115 (11.1)
>10 752 (72.4)
Number of preventive outpatient health care visits within
5 years of reference date
0 411 (39.6)
1 251 (24.2)
2-3 243 (23.4)
4+ 134 (12.9)
Family history of colorectal cancer (CRC)† 96 (9.2)
Charlson comorbidity index at baseline‡
0 842 (81.0)
1 148 (14.2)
2+ 49 (4.7)
Had a healthcare visit during the 2-year period at baseline‡ 161 (15.5)
Undergone colonoscopy 524 (50.4)
Had ≥2 colonoscopies 88 (8.5)
*Households below 1999 federal poverty levels within the block-group from
2000 decennial census measures. Higher quartiles correspond to higher levels
of household poverty in the census block-group.
†This variable refers to family history that did not meet the exclusion – those
with a history of colorectal cancer diagnosed in any first degree relative before
age 50 or 2 or more relatives of any age, or other familial syndromes.
‡Baseline refers to the 2-year period at the beginning of each patient’s
observation period.
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studies have described the use of adjudication in systemat-
ically assigning indication. Most reports using medical re-
cords derive indication from the procedure report alone
and in some cases the source of the indication information
in the medical records was not clearly described [18,33-36].
Our findings suggest that approaches using only the pro-
cedure report or referral notes may be subject to a greater
degree of misclassification, possibly because the indication
documented may be influenced by examination findings
or the need to obtain third-party payer approval for the
referral.
Our study has several important implications. First,
compared with adjudication, all of the sources of infor-
mation demonstrated some misclassification, particularly
for ‘high-risk’ indications. Second, the procedure report
had the fewest missing indications, but produced effect
sizes that differed slightly more from the adjudicated re-
sults than the progress notes. Third, the progress notes
data produced estimates of screening that were consist-
ently closest to those from adjudication, suggesting that
the details from progress notes are important for accur-
ate indication classification. Thus, our study suggests
that review of data in the progress notes in medical
records, including detailed information on clinical con-
ditions documented around the time of the test, is re-
quired to produce valid results in observational studies
of CRC screening effectiveness. Finally, if resources are
limited, adjudication of indication may focus on ‘high-
risk’ and ‘unknown’ test indications. If adjudication is
not performed, given their relative rarity, including
‘high-risk’ indication as screening is preferable to exclud-
ing them in analyses of effects on average-risk persons.
Figure 3 Percentage distribution of colonoscopy indication by medical records data sources and targeted adjudication, at the test-level
and analytic or patient-level. *The numbers are the percentages in each classification group for colonoscopies in Figure 3A or patients in Figure
3B. There were 647 colonoscopies observed in 524 patients. The distribution of indication in Figure 3B, correspond to the analytic variable. Each
of the colored sections of the stacked bars represents the classification of the indication as shown in the legend. The “all sources combined”
indication is assigned with data from all sources using the classification algorithm.
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This study has some limitations. Because the original
study was for average-risk persons, some high-risk pa-
tients were excluded at the time of patient selection.
Therefore, tests for high-risk indications may be un-
derrepresented in this analysis. Abstractors were not
blinded to the source of information in the medical re-
cords, possibly contributing to the high correlation of
indication across data sources. Also, not all tests were
adjudicated, and reviewers did not have access to all
the medical record data, including detailed information
Figure 4 Agreement on colonoscopy indication classification across three medical records data sources: test-level and patient-level
analysis. The percentages are the observed agreement and the proportions are the weighted kappa (ĸ) statistic. *The numbers in the circles are
the patient-level analyses results.
Table 2 Association between screening colonoscopy and risk of incident late-stage CRC according to data source,
SEARCH Study 2006–2008, n = 1,039
Data source according to screening definition used Odds Ratio and 95% CI % Difference in beta coefficients P-value of difference*
Screening defined as ‘probable’ or ‘definite’
Progress note 0.31 (0.14-0.70) −9.5 0.64
Referral note 0.46 (0.22-0.98) 28.0 0.41
Procedure report 0.50 (0.25-1.02) 31.2 0.26
All sources combined 0.30 (0.14-0.65) −21.6 0.52
Adjudicated indication 0.36 (0.19-0.68) Ref Ref
Same definition as above plus ‘high-risk’ screening exposures
Progress note 0.32 (0.17-0.64) 2.4 0.98
Referral note 0.45 (0.23-0.85) 34.9 0.12
Procedure report 0.43 (0.23-0.79) 27.4 0.23
All sources combined 0.31 (0.16-0.58) −6.2 0.69
Adjudicated indication 0.33 (0.17-0.62) Ref Ref
Conditional logistic regression modelling was performed with separate indicator variables for colonoscopy and sigmoidoscopy and adjusted for receipt of
‘definite’ screening barium enema and FOBT, census block-group poverty levels (as a continuous variable), number of preventive health care visits, family history
of colorectal cancer, and comorbidity index at baseline. Missing values of poverty level were imputed using predictive mean matching.
*Two-sided Wald Chi-square (χ2) P-values of the difference between effect sizes.
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on the duration and severity of clinical conditions that
were recorded as reasons for testing. Further, the dis-
tribution of colonoscopy indications, and thus the use-
fulness and necessary extent of adjudication, may vary
across settings, depending on population demograph-
ics and reimbursement policies. Future larger studies
in non-managed care settings and in different settings
or populations are needed to establish the benefits of
obtaining data from multiple sources and conducting
adjudication for indication classification. Additional
studies are also needed to evaluate the impact of indi-
cation misclassification on estimates of the effective-
ness of colonoscopy for reducing risk of CRC death.
Further, the approaches described in this paper can be
applied to evaluate the degree to which indication mis-
classification biases results of colonoscopy effective-
ness in studies based on administrative data.
Conclusions
Careful classification of indication is important in obser-
vational research on the comparative effectiveness of
CRC screening tests and in the quality improvement of
CRC testing. In our study, we found no single gold-
standard source of information in the medical records
for indication classification that agreed consistently with
expert adjudication, and the data sources were comple-
mentary in achieving better indication classification. Adju-
dication changed the classification of some indications and
the data-source differences we observed resulted in some
deviations in the odds ratios for the association between
screening colonoscopy and late-stage CRC risk. The devia-
tions from the adjudicated standard for this association
were smaller with progress notes information than with
other sources alone. Therefore, careful standardized reviews
of information in the progress notes, referral notes and pro-
cedure report are necessary for accurate classification of
colonoscopy indication.
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